GE HealthCare stock gains BTIG support as imaging orders drive outlook

GE HealthCare Technologies Inc. stock (ISIN US36266G1076) is back in the analyst spotlight after BTIG reiterated a Buy rating and maintained a USD 79.00 price target on September 17, 2026, highlighting positive feedback for the company’s next-generation photon-counting CT system and a solid order backdrop.Investing.com As of September 16, 2026, the shares traded around USD 63.49 on Nasdaq, implying roughly 24 percent upside to BTIG’s target.

Analysts back imaging-led growth

According to Investing.com on September 17, 2026, BTIG reaffirmed its Buy stance on GE HealthCare stock and lifted its price target to USD 79 from USD 75, citing strong order trends and encouraging clinician feedback on the Photonova Spectra photon-counting CT system.

BTIG’s latest note points to year-to-date price weakness as a potential opportunity: GE HealthCare shares at USD 63.49 were about 22 percent lower than at the start of 2026,Investing.com while the firm’s USD 79.00 price target implies approximately 24.4 percent upside from the September 16, 2026 close.TradingView/Benzinga

Second-quarter results beat expectations

In its most recent available quarter, GE HealthCare reported second-quarter revenue of USD 5.295 billion, representing 3.5 percent organic growth year over year and modestly beating Oppenheimer’s estimate of USD 5.277 billion as well as the consensus figure of USD 5.264 billion.Investing.com Adjusted earnings per share for that quarter came in at USD 1.13, ahead of Oppenheimer’s USD 1.05 estimate and the broader consensus of USD 1.04, underscoring better-than-expected profitability.Investing.com

Beyond the headline numbers, the company reported an 11.1 percent increase in organic orders in the same second quarter, the fastest pace since its spin-off from General Electric, signaling robust demand for imaging and diagnostics equipment.Investing.com GE HealthCare reiterated its organic revenue growth guidance of 3 to 4 percent for 2026 and reported a backlog of USD 23.9 billion, giving investors visibility into future revenue streams.Investing.com

Valuation and consensus view

Per data compiled by MarketBeat on September 16, 2026, GE HealthCare stock traded around USD 63.78 on Nasdaq, placing it close to the lower end of its 52-week range between USD 58.75 and USD 89.77 and giving the company a market capitalization of roughly USD 28.8 billion.

The same MarketBeat overview cites a trailing twelve-month EPS of USD 4.36 and a price-to-earnings ratio of about 14.6, which is below both the broader US market’s average and the healthcare sector’s average multiples.MarketBeat Analysts tracked by MarketBeat assign GE HealthCare a consensus rating of Hold, with a consensus price target of USD 77.73 implying about 22 percent upside from the current price region and individual targets ranging up to USD 98.00.MarketBeat

Legal investigation highlights recall risk

While the recent analyst commentary has been supportive, investors also face headline risk from an ongoing securities fraud investigation focused on how GE HealthCare communicated around a product recall and margin pressures earlier in the year. The Law Offices of Frank R. Cruz noted on September 16, 2026 that it continues to examine potential violations of federal securities laws tied to the company’s first-quarter 2026 results and subsequent share price reaction.GlobeNewswire

According to the same GlobeNewswire release dated September 16, 2026, GE HealthCare reported adjusted EPS of USD 0.99 in the first quarter of 2026 and reduced its full-year 2026 adjusted EPS guidance to a range of USD 4.80 to USD 5.00, down from a prior band of USD 4.95 to USD 5.15.GlobeNewswire Management attributed the margin pressure partly to a recall involving a pharmaceutical diagnostics supplier and weaker performance in its PCS business, and the stock fell USD 9.01, or 13.2 percent, to close at USD 59.49 on April 29, 2026, following the disclosure.GlobeNewswire

Stock level and investor takeaway

With GE HealthCare stock trading around USD 63.78 on Nasdaq as of September 16, 2026, investors are looking at a price that sits only modestly above the 52-week low of USD 58.75 and well below the 52-week high of USD 89.77,MarketBeat a setup that frames both the BTIG upside case and the legal investigation risk.

More news and analyses on GE HealthCare stock